JAK/HDAC-IN-3, identified by its CAS number 3029138-70-0, is a small molecule inhibitor that targets both Janus kinases (JAKs) and histone deacetylases (HDACs). This dual inhibition is significant in the context of cancer research and treatment, as it can modulate various signaling pathways involved in cell proliferation, differentiation, and apoptosis. The compound is characterized by its ability to interfere with the JAK-STAT signaling pathway, which is often dysregulated in various malignancies, and its action on HDACs, which play a crucial role in the regulation of gene expression through chromatin remodeling. JAK/HDAC-IN-3 has been studied for its potential therapeutic effects in hematological malignancies and solid tumors, showcasing a promising profile in preclinical models. Its chemical structure and properties facilitate its function as a potent inhibitor, making it a subject of interest in drug development aimed at overcoming resistance mechanisms in cancer therapy. Further research is ongoing to fully elucidate its pharmacokinetics, efficacy, and safety profile in clinical settings.

JAK/HDAC-IN-3

3029138-70-0: JAK/HDAC-IN-3, identified by its CAS number 3029138-70-0, is a small molecule inhibitor that targets both Janus kinases (JAKs) and histone deacetylases (HDACs). This dual inhibition is significant in the context of cancer research and treatment, as it can modulate various signaling pathways involved in cell proliferation, differentiation, and apoptosis. The compound is characterized by its ability to interfere with the JAK-STAT signaling pathway, which is often dysregulated in various malignancies, and its action on HDACs, which play a crucial role in the regulation of gene expression through chromatin remodeling. JAK/HDAC-IN-3 has been studied for its potential therapeutic effects in hematological malignancies and solid tumors, showcasing a promising profile in preclinical models. Its chemical structure and properties facilitate its function as a potent inhibitor, making it a subject of interest in drug development aimed at overcoming resistance mechanisms in cancer therapy. Further research is ongoing to fully elucidate its pharmacokinetics, efficacy, and safety profile in clinical settings.

<p>JAK/HDAC-IN-3 (13a), a dual inhibitor of JAK and HDAC, exhibits IC50 values of 25.36 nM for JAK2, 0.2 μM for HDAC, and 0.43 μM for HDAC1, respectively [1].</p>

CAS 3029138-70-0

JAK/HDAC-IN-3

JAK/HDAC-IN-3

Ref: TM-T86754